寧波精達(603088.SH)涉嫌信披違法違規 遭中證監立案調查
格隆匯11月1日丨寧波精達(603088.SH)公佈,公司於2019年11月1日收到中國證監會《調查通知書》(編號:甬證調查字2019067號),因公司涉嫌信息披露違法違規,根據《中華人民共和國證券法》的有關規定,中國證監會決定對公司立案調查。
同日,公司控股股東寧波成形控股有限公司,實際控制人一致行動人寧波精微投資有限公司,寧波廣達投資有限公司,徐儉芬分別收到中國證監會《調查通知書》(甬證調查字2019068號,甬證調查字2019069號,甬證調查字2019070號,甬證調查字2019071號)。因涉嫌信息披露違法違規,根據《中華人民共和國證券法》的有關規定,中國證監會決定對上述公司及個人立案調查
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.